Drugs / HS-130
last change Apr 2022 re-read 2 minutes ago

HS-130

Vaccine

Developed for
neoplasm
Investigated by
Heat Biologics

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04116710 Oct 2019 → Aug 2021 neoplasm Heat Biologics Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HS-130 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04116710
Modality Vaccine Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig” NCT04116710